Valuation: argenx SE

Capitalization 42.01B 48.9B 38.44B 36.51B 67.22B 4,711B 68.37B 460B 178B 2,229B 184B 180B 7,769B P/E ratio 2026 *
28.9x
P/E ratio 2027 * 21.9x
Enterprise value 37.45B 43.59B 34.26B 32.54B 59.92B 4,199B 60.94B 410B 159B 1,987B 164B 160B 6,925B EV / Sales 2026 *
7.36x
EV / Sales 2027 * 5.72x
Free-Float
100%
Yield 2026 *
0.06%
Yield 2027 * 0.13%
1 day-2.54%
1 week-2.26%
Current month+1.14%
1 month-5.88%
3 months-5.43%
6 months-14.33%
Current year-5.75%
1 week 674.8
Extreme 674.8
705.6
1 month 646
Extreme 646
719.4
Current year 568.4
Extreme 568.4
738
1 year 456.6
Extreme 456.6
810
3 years 271
Extreme 271
810
5 years 201.4
Extreme 201.4
810
10 years 10.15
Extreme 10.15
810
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2026
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman 54 06/05/2026
Director/Board Member 76 13/05/2015
Director/Board Member 65 28/04/2016
Change 5d. change 1-year change 3-years change Capi.($)
-2.54%-2.26%+33.94%+75.07% 50.1B
-1.05%-6.14%+66.31%+52.72% 45.82B
-1.82%+3.14%+57.30%+469.34% 23.66B
-0.78%-4.81%-4.23%-15.34% 22.65B
-2.20%-0.36%+39.87%-24.45% 17.8B
+0.39%+1.90%+27.97%-40.10% 16.08B
-5.32%-13.33%+36.29%+207.57% 14.14B
-5.04%-14.15%-32.89%+888.89% 13.09B
-2.84%-5.57%+32.07% - 13B
-0.58%+0.26%+9.78%+152.61% 12.6B
Average -2.18%-3.98%+26.64%+196.26% 22.89B
Weighted average by Cap. -1.98%-3.81%+33.99%+149.81%

Financials

2026 *2027 *
Net sales 5.09B 5.92B 4.66B 4.42B 8.14B 571B 8.28B 55.72B 21.6B 270B 22.23B 21.76B 941B 6.19B 7.2B 5.66B 5.38B 9.9B 694B 10.07B 67.78B 26.27B 328B 27.03B 26.46B 1,144B
Net income 1.51B 1.75B 1.38B 1.31B 2.41B 169B 2.45B 16.51B 6.4B 79.99B 6.59B 6.45B 279B 2.07B 2.41B 1.89B 1.8B 3.31B 232B 3.37B 22.67B 8.79B 110B 9.04B 8.85B 383B
Net Debt -4.56B -5.31B -4.18B -3.97B -7.3B -512B -7.43B -49.98B -19.37B -242B -19.94B -19.51B -844B -6.61B -7.69B -6.05B -5.74B -10.58B -741B -10.76B -72.39B -28.06B -351B -28.87B -28.26B -1,222B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
18/05/26 675.60 -2.54% 77,077
15/05/26 693.20 -0.14% 80,984
14/05/26 694.20 +1.02% 50,077
13/05/26 687.20 -1.58% 75,044
12/05/26 698.20 +1.01% 87,162
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
675.60EUR
Average target price
846.68EUR
Spread / Average Target
+25.32%

Quarterly revenue - Rate of surprise